Aspirin Pain Inflammation 20 Tablets 500 Mg

€9.65
Tax included
Brand
Minsan
041962034
100% secure payments
Hurry up! Only 89 item(s) left in Stock!
Quantity

WARNINGS
In case of combination with other medicinal products, to avoid any risk of overdose, check that acetylsalicylic acid is absent from the composition of these other medicines. Reye's syndrome, a very rare and life-threatening disease, has been described in children with symptoms of viral infections (particularly chicken pox and flu episodes) with or without acetylsalicylic acid. Consequently, acetylsalicylic acid should only be given to children with these conditions after medical advice and when other measures have proved ineffective. In case of persistent vomiting, changes in consciousness or abnormal behavior, treatment with acetylsalicylic acid should be discontinued. In case of prolonged administration of high-dose analgesics, the headache attack should not be treated with higher doses. The regular use of analgesics, particularly a combination of analgesics, can lead to permanent kidney damage, with the risk of renal failure. In some severe forms of G6PD deficiency, high doses of acetylsalicylic acid can cause hemolysis. In case of G6PD deficiency, acetylsalicylic acid should be administered under medical supervision. Treatment monitoring should be intensified in the following cases: in patients with a history of gastric or duodenal ulcer, gastrointestinal bleeding, or gastritis; in patients with renal insufficiency; in patients with hepatic insufficiency; in patients with asthma: the occurrence of an asthma attack, in some patients, may be linked to an allergy to non-steroidal anti-inflammatory drugs or acetylsalicylic acid; in this case, this medicine is contraindicated; in patients with metrorrhagia or menorrhagia (risk of an increase in volume and duration of the cycle). Gastrointestinal bleeding or ulcers / perforations can occur at any time during treatment, without necessarily having any warning signs or history in the patient. The relative risk increases in elderly subjects, in subjects with low body weight, and in patients receiving anticoagulants or platelet aggregation inhibitors. In case of gastrointestinal bleeding, treatment should be stopped immediately. Given the inhibitory effect of acetylsalicylic acid on platelet aggregation, which occurs even at very low doses and persists for several days, the patient should be aware of the risk of haemorrhage in the event of surgery, even of a small entity ( e.g. tooth extraction). In analgesic or antipyretic doses, acetylsalicylic acid inhibits the excretion of uric acid; in the doses used in rheumatology (anti-inflammatory doses), acetylsalicylic acid has a uricosuric effect. The use of this medicine is not recommended during breastfeeding. Administration of acetylsalicylic acid is not recommended with: oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid (> = 500 mg per administration and / or <3 g per day) and in patients without a history of gastro-duodenal ulcers. Other non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid (> = 1 g per administration and / or> = 3 g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (> = 500 mg per administration and / or < 3 g per day). Low molecular weight heparins (and related molecules) and unfractionated heparins with therapeutic doses or in elderly patients (> 65 years) regardless of heparin dose, and for anti-inflammatory doses of acetylsalicylic acid (> = 1g per administration and / or> = 3 g per day) or with analgesic or antipyretic doses of acetylsalicylic acid (> = 500 mg per administration and / or <3 g per day); clopidogrel (beyond the approved indications for this combination in patients with acute coronary artery disease); ticlopidine; uricosurics; glucocorticoids (except for hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid (> = 1 g per administration and / or> = 3 g per day); pemetrexed in patients with mildly to moderately impaired renal function (creatinine clearance between 45 ml / min and 80 ml / min); anagrelide: increased risk of haemorrhage and decreased antithrombotic effect.
PHARMACOTHERAPEUTIC CATEGORY
Analgesics and antipyretics.
STORAGE
Do not store above 30 degrees C.
CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to acetylsalicylic acid or other salicylates, or to any of the excipients; history of asthma or hypersensitivity reactions' (e.g. urticaria, angioedema, severe rhinitis, shock) induced by the administration of salicylates or substances with similar action, in particular non-steroidal anti-inflammatory drugs (NSAIDs); active peptic ulcer; hemorrhagic diathesis; severe renal failure; severe hepatic insufficiency; severe uncontrolled heart failure; concomitant administration of methotrexate in doses greater than 20 mg per week, for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses; concomitant administration of oral anticoagulants for anti-inflammatory doses of acetylsalicylic acid, or for analgesic or antipyretic doses and in patients with a history of gastroduodenal ulcers; from the beginning of the sixth month of pregnancy (beyond the twenty-fourth week of amenorrhea); children and young people under 16 years of age.
NAME
ASPIRIN PAIN AND INFLAMMATION 500 MG
EXCIPIENTS
Tablet core: colloidal silicon dioxide; anhydrous sodium carbonate. Coating: carnauba wax; hypromellose; zinc stearate.
SIDE EFFECTS
Frequencies: not known (cannot be estimated from the available data). Disorders of the blood and lymphatic system: bleeding and bleeding tendency (epistaxis, bleeding gums, purpura, etc.) with increased bleeding time. The risk of bleeding may persist for 4-8 days after stopping the intake of acetylsalicylic acid. It can cause an increased risk of bleeding in case of surgery. Intracranial and gastrointestinal bleeding can also occur. Immune system disorders: hypersensitivity reactions, anaphylactic reactions, asthma, angioedema. Nervous system disorders: headache, dizziness, sensation of hearing loss, tinnitus, usually indicating an overdose. Intracranial hemorrhage. Gastrointestinal disorders: abdominal pain. Occult or overt gastrointestinal bleeding (haematemesis, melaena, etc.) resulting in iron deficiency anemia. The risk of bleeding is dose related. Gastric ulcers and perforations. Hepatobiliary disorders: hepatic enzyme elevations usually reversible on discontinuation of treatment, liver damage, mainly of hepatocellular nature Skin and subcutaneous tissue disorders: urticaria, rash General disorders Reye's syndrome. It is important to report side effects of the medicine after authorization. This allows you to continue monitoring the benefit-risk balance of the medicine.
PREGNANCY AND BREASTFEEDING
Inhibition of prostaglandin synthesis can have adverse effects on the course of pregnancy and / or embryo-fetal development. Data from epidemiological studies suggest an increased risk of spontaneous abortion, cardiac malformations and gastroschisis following the use of prostaglandin synthesis inhibitors in early pregnancy. The risk appears to increase with dose and duration of treatment. In animals, administration of a prostaglandin synthesis inhibitor has been shown to cause an increase in pre- and post-implantation loss and embryo-fetal mortality. Furthermore, an increased incidence of various malformations, including cardiovascular ones, has been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period of gestation. Unless absolutely necessary, acetylsalicylic acid should not be given during the first 24 weeks of amenorrhea. If acetylsalicylic acid is administered to women who wish to become pregnant or are pregnant during the first 24 weeks of amenorrhea, the dose should be as low as possible and the duration of treatment as short as possible. Beyond 24 weeks of amenorrhea, all prostaglandin synthesis inhibitors can expose the fetus to: cardiopulmonary toxicity (with premature closure of the arterial duct and pulmonary hypertension); renal dysfunction, which can lead to renal failure with oligohydroamniosis; In the final phase of pregnancy, the mother and the newborn may experience: prolongation of the bleeding time, due to the inhibition of platelet aggregation which can occur even at very low doses of acetylsalicylic acid; inhibition of uterine contractions which causes the delay or prolongation of labor. Therefore acetylsalicylic acid is contraindicated after the fifth month of pregnancy (over 24 weeks of amenorrhea). Acetylsalicylic acid passes into breast milk: therefore the use of acetylsalicylic acid is not recommended during breastfeeding. There is some evidence that drugs that inhibit cyclooxygenase / prostaglandin synthesis can cause impaired female fertility due to an effect on ovulation. This effect is reversible upon discontinuation of treatment.
INDICATIONS
Symptomatic treatment of fever and / or mild to moderate pain, such as headache, flu syndrome, toothache, muscle aches.
INTERACTIONS
In the following text, the following definitions apply: anti-inflammatory doses of acetylsalicylic acid are defined as "> = 1g per administration and / or> = 3g per day"; analgesic or antipyretic doses of acetylsalicylic acid are defined as "> = 500 mg per administration and / or <3 g per day". Several substances give rise to interactions, due to their properties of platelet aggregation inhibitors: abciximab, acetylsalicylic acid, cilostazol, clopidogrel, epoprostenol, eptifibatide, iloprost, iloprost trometamol, prasugrel, ticlopidine, tirofiban, ticagrelor. The risk of bleeding increases with the use of multiple platelet aggregation inhibitors as well as with their use in combination with heparin or related molecules, oral anticoagulants or other thrombolytics, and must be evaluated by constant clinical monitoring. >> Combinations contraindicated. Methotrexate in doses higher than 20 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, in particular haematological toxicity (due to the reduced renal elimination of methotrexate caused by 'acetylsalicylic acid). Oral anticoagulants with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid and in patients with a history of gastroduodenal ulcers: increased risk of bleeding. >> Combinations not recommended. Oral anticoagulants with analgesic or antipyretic doses of acetylsalicylic acid and in patients without a history of gastroduodenal ulcers: increased risk of bleeding. Other non-steroidal anti-inflammatory drugs (NSAIDs) with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and bleeding. Low molecular weight heparins (and related molecules) and unfractionated heparins at curative doses, or in elderly patients (> = 65 years) regardless of heparin dose, and for anti-inflammatory doses of acetylsalicylic acid or analgesic or antipyretic doses of acetylsalicylic acid: increased risk of bleeding (inhibition of platelet aggregation and aggression of the gastroduodenal mucosa by acetylsalicylic acid). Another anti-inflammatory drug, or another analgesic or antipyretic, should be used. Clopidogrel (outside the approved indication for this combination in patients with acute coronary syndrome): increased risk of haemorrhage. If concomitant administration cannot be avoided, clinical monitoring is recommended. Ticlopidine: increased risk of bleeding. If concomitant administration cannot be avoided, clinical monitoring is recommended. Uricosurics (benzbromarone, probenecid): reduction of the uricosuric effect due to competition for the elimination of uric acid in the renal tubules. Glucocorticoids (excluding hydrocortisone replacement therapy) for anti-inflammatory doses of acetylsalicylic acid: increased risk of bleeding. Pemetrexed in patients with mild to moderate impairment of renal function (creatinine clearance between 45 ml / min and 80 ml / min); increased risk of pemetrexed toxicity (due to decreased renal elimination of pemetrexed by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Anagrelide: increased risk of haemorrhage and decreased antithrombotic effect. If concomitant administration cannot be avoided, clinical monitoring is recommended. >> Combinations that require precautions for use. Diuretics, angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, with anti-inflammatory doses of acetylsalicylic acid or with analgesic or antipyretic doses of acetylsalicylic acid: acute renal failure may occur in dehydrated patients caused by the reduction of the glomerular filtration rate due to the decreased synthesis of renal prostaglandins. Furthermore, there may be a reduction in the antihypertensive effect. Ensure that the patient is hydrated and that renal function is monitored at the start of treatment. Methotrexate in doses <= 20 mg per week, with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased toxicity of methotrexate, particularly haematological toxicity (due to the reduced renal elimination of methotrexate caused 'acetylsalicylic acid). Complete blood counts should be monitored weekly during the first few weeks of concomitant administration. Patients with reduced (even mild) renal function and elderly patients should be closely monitored. Clopidogrel (in the approved indication for this combination in patients with acute coronary syndrome): increased risk of haemorrhage. Clinical monitoring is recommended. Topical gastrointestinal treatments, antacids and activated charcoal: increased renal excretion of acetylsalicylic acid due to alkalinization of the urine. It is recommended that antacids and topical gastrointestinal treatments be administered at least two hours after taking acetylsalicylic acid. Pemetrexed in patients with normal renal function: increased risk of toxicity from pemetrexed (due to the decreased renal elimination of pemetrexed caused by acetylsalicylic acid) with anti-inflammatory doses of acetylsalicylic acid. Kidney function should be monitored. >> Combinations that must be taken into account. Glucocorticoids (excluding hydrocortisone replacement therapy) for analgesic and antipyretic doses of acetylsalicylic acid: increased risk of haemorrhage. Deferasirox: with anti-inflammatory doses of acetylsalicylic acid, or with analgesic or antipyretic doses of acetylsalicylic acid: increased risk of gastrointestinal ulcers and bleeding. Low molecular weight heparins (and related molecules) and unfractionated heparins in preventive doses in patients <65 years of age: by affecting haemostasis at various levels, concomitant administration increases the risk of haemorrhage. Therefore, in such patients, the co-administration of heparins (or related molecules) in preventive doses, and of acetylsalicylic acid in any dose, should be considered in conjunction with clinical and laboratory monitoring as needed. Thrombolytics: increased risk of bleeding. Selective Serotonin Reuptake Inhibitors: increased risk of bleeding.
DOSAGE
Adults and children (from 16 years onwards): from 1 to 2 tablets for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 6 tablets. Elderly (from 65 years): 1 tablet for each dose to be repeated as needed after a minimum period of 4 hours. The maximum daily dose should not exceed 4 tablets. Acetylsalicylic acid should not be taken for more than 3 days (in case of fever) or 3 - 4 days (in case of pain) unless otherwise indicated by the doctor. Pediatric population: Acetylsalicylic acid should not be used in children and adolescents under the age of 16 without a prescription. Acetylsalicylic acid should be used with caution in patients with abnormal liver or kidney function or with circulatory problems. Method of administration: for oral use. The tablets should be taken with an adequate amount 'of liquids.
ACTIVE PRINCIPLES
Acetylsalicylic acid.
Bayer
041962034
89 Items

Specific References

chat Comments (0)
No customer reviews for the moment.

Aspirin Pain Inflammation...

€9.65